
Pharmafocus spoke to John Crowley, CEO of Amicus Therapeutics, about his highly unusual career in the pharmaceutical and biotech industries.

Astellas, under the direction of new CEO, Kenji Yasukawa, has unveiled a major new restructure, ahead of a difficult looking …

The European Commission has given its approval to Sandoz, Novartis’ generics and biosimilars unit, for its biosimilar version of Janssen’s …

A report published by the Institute for Fiscal Studies (IFS) has stressed that UK funding into the NHS needs to …

MSD Keytruda has enjoyed the most success of the PD-1/L1 therapies in clinical trials recently and it’s rapidly cementing its …

The joint partnership between Vifor Pharma and Fresenius Medical Care, Vifor Fresenius, has put down $50 in upfront cash and …

Sun Pharma is celebrating with the announcement that its CYP17 inhibitor Yonsa (abiraterone acetate) has been awarded FDA approval in …

The latest global research paints a bleak picture of future global public health, predicting that almost a quarter of the …

The ongoing opioid epidemic in the US has seen the rise of the sale and use of kratom (mitragyna speciose), …

Much has already been written about Takeda and its massive financial stretch to pull in the Shire acquisition, in the …

A first-of-its-kind collaboration has been announced by the governments of India, Sweden and The Netherlands with the goal of advancing …

The Royal Liverpool and Broadgreen University Hospitals NHS Trust has teamed up with a provider of AI systems to introduce …

Professor Mel Greaves, of The Institute of Cancer Research, has spent 30 years uncovering what is behind the mysterious rise …

ViiV Healthcare has announced that its HIV therapy Juluca (dolutegravir/rilpivirine) has been awarded marketing authorisation in the EU from the …

Nabriva Therapeutics, a biotech based in Dublin, Ireland, has announced positive Phase 3 data for its antibiotic, lefamulin, which could …

Gilead has unveiled the expansion of its Cork manufacturing site, involved in the creation of its treatments for HIV and …

Gene Matthews, Partner at Leigh Day, reviews the tough decisions the UK has to make regarding its position in the …

The EMA has judged that the benefits offered by Zinbryta (daclizumab), Abbvie and Biogen’s humanised IgG1 monoclonal antibody for the …

Hemlibra was widely expected to become the dominant therapeutic for treating haemophilia patients and its latest clinical trial results only …

The FDA has revealed its decision to approve AstraZeneca’s oral potassium-removing agent Lokelma (sodium zirconium cyclosilicate) for the treatment of …